These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 21266847)
41. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity. Bustamante PJ; Woodruff DC; Oh J; Keister DB; Muratova O; Williamson KC Parasite Immunol; 2000 Aug; 22(8):373-80. PubMed ID: 10972844 [TBL] [Abstract][Full Text] [Related]
42. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. de Graaf H; Payne RO; Taylor I; Miura K; Long CA; Elias SC; Zaric M; Minassian AM; Silk SE; Li L; Poulton ID; Baker M; Draper SJ; Gbesemete D; Brendish NJ; Martins F; Marini A; Mekhaiel D; Edwards NJ; Roberts R; Vekemans J; Moyle S; Faust SN; Berrie E; Lawrie AM; Hill F; Hill AVS; Biswas S Front Immunol; 2021; 12():694759. PubMed ID: 34335606 [TBL] [Abstract][Full Text] [Related]
43. The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines. Espinosa DA; Vega-Rodriguez J; Flores-Garcia Y; Noe AR; Muñoz C; Coleman R; Bruck T; Haney K; Stevens A; Retallack D; Allen J; Vedvick TS; Fox CB; Reed SG; Howard RF; Salman AM; Janse CJ; Khan SM; Zavala F; Gutierrez GM Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895131 [TBL] [Abstract][Full Text] [Related]
44. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum. Kapulu MC; Da DF; Miura K; Li Y; Blagborough AM; Churcher TS; Nikolaeva D; Williams AR; Goodman AL; Sangare I; Turner AV; Cottingham MG; Nicosia A; Straschil U; Tsuboi T; Gilbert SC; Long CA; Sinden RE; Draper SJ; Hill AV; Cohuet A; Biswas S Sci Rep; 2015 Jun; 5():11193. PubMed ID: 26063320 [TBL] [Abstract][Full Text] [Related]
45. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Lobo CA; Dhar R; Kumar N Infect Immun; 1999 Apr; 67(4):1688-93. PubMed ID: 10085005 [TBL] [Abstract][Full Text] [Related]
46. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. Jones RM; Chichester JA; Mett V; Jaje J; Tottey S; Manceva S; Casta LJ; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Mett V; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V PLoS One; 2013; 8(11):e79538. PubMed ID: 24260245 [TBL] [Abstract][Full Text] [Related]
47. Efficacy model for mosquito stage transmission blocking vaccines for malaria. Saul A Parasitology; 2008 Nov; 135(13):1497-506. PubMed ID: 18257944 [TBL] [Abstract][Full Text] [Related]
48. Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds. Da DF; Dixit S; Sattabonkot J; Mu J; Abate L; Ramineni B; Ouedraogo JB; MacDonald NJ; Fay MP; Su XZ; Cohuet A; Wu Y Infect Immun; 2013 Jun; 81(6):1984-9. PubMed ID: 23509152 [TBL] [Abstract][Full Text] [Related]
55. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Kumar R; Ray PC; Datta D; Bansal GP; Angov E; Kumar N Vaccine; 2015 Sep; 33(39):5064-71. PubMed ID: 26299750 [TBL] [Abstract][Full Text] [Related]
56. A Viral-Vectored Multi-Stage Malaria Vaccine Regimen With Protective and Transmission-Blocking Efficacies. Yusuf Y; Yoshii T; Iyori M; Mizukami H; Fukumoto S; Yamamoto DS; Emran TB; Amelia F; Islam A; Syafira I; Yoshida S Front Immunol; 2019; 10():2412. PubMed ID: 31681301 [TBL] [Abstract][Full Text] [Related]
57. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Theisen M; Roeffen W; Singh SK; Andersen G; Amoah L; van de Vegte-Bolmer M; Arens T; Tiendrebeogo RW; Jones S; Bousema T; Adu B; Dziegiel MH; Christiansen M; Sauerwein R Vaccine; 2014 May; 32(22):2623-30. PubMed ID: 24662702 [TBL] [Abstract][Full Text] [Related]